B ERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall ...
Breast cancer affects many women globally. While most cases are random, some stem from inherited genes like BRCA1 and BRCA2.
Without an easy way to screen and with nondescript symptoms, ovarian cancer is often caught in late stages, requiring massive ...
Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to ...
A seven-time Olympic medalist was diagnosed with ovarian cancer after missing the same three warning signs common in early ...
Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...
Three years after beating cancer, a senior physician suffered a serious bout of pneumonia that left her hospitalised.Dr Emily ...
R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...
Emily Pwee, 54, developed a fever and cough on Oct. 10, her husband, 54-year-old Jimmy Teo, told Shin Min Daily News . Teo, a ...
Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...